This phase III study is evaluating how effective a new immunotherapy drug (IO102-IO103) is in combination with another immunotherapy drug (pembrolizumab), compared to pembrolizumab alone, in people with previously untreated, advanced melanoma.
This trial is treating patients with advanced or metastatic melanoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18)
Commercial Sponsor
IO Biotech
Summary
Eligible participants will be randomly assigned to either the Experimental Arm or the Active Comparator Arm. All participants will receive pembrolizumab (200mg) administered intravenously every 3 weeks for a maximum of 35 cycles. Participants assigned to the Experimental Arm will also receive IO102-IO103 every three weeks with an additional dose given during the induction period on Day 8 of cycles 1 and 2. IO102-IO103 will thereafter be administered subcutaneously every 3 weeks during the maintenance period.
Recruiting Hospitals Read More